We4 Insights
Healthcare is evolving, and so is innovation.
Join our community to explore the latest insights on digital health, clinical research, telemedicine, and regulatory transformation.
Get updates, expert perspectives, and thought
leadership delivered straight to your inbox.
Stay informed. Stay ahead.
Healthcare evolves fast and innovation doesn’t wait.
Subscribe to receive updates on digital health, clinical research, telemedicine,
and regulatory strategy.
Expert insights, real-world perspectives, and key events from the We4 ecosystem delivered directly to your inbox.
Because better decisions start with better knowledge.
PMCF under MDR: from regulatory obligation to competitive advantage
In many medical device companies, Post-Market Clinical Follow-up (PMCF) is still seen as a burden — a bureaucratic requirement introduced by the EU MDR (EU 2017/745) that adds cost and pressure to already overloaded regulatory teams. That view is increasingly short-sighted.Companies that treat PMCF purely as compliance are missing a significant strategic opportunity. The MDR…
Real-World Evidence and MDR: why post-market data often matters more than trials
There is a paradox in medical device research that is rarely discussed openly. The most controlled, expensive and rigorously monitored method of generating clinical evidence (the interventional trial) often produces evidence that becomes less useful once the device enters real clinical practice. Clinical trials typically ask: Does the device work under optimal conditions, with selected…
Innovative medical device in 2026: how to build an evidence strategy that holds…without drowning in rework
There’s a sentence we hear often from founders, Clinical Affairs and Regulatory teams: “We have a strong device, but we’re afraid of losing time.” Not time spent working.Time lost to rework, the kind that appears halfway through a study, when you realize it started… but wasn’t solid enough. Studies don’t fail because there’s a lack…
Risk-based means protecting what matters most
In clinical research, risk-based approaches are everywhere: they appear in protocols, monitoring plans, and quality systems. But there is a growing misunderstanding. Many organizations treat risk-based as a justification to reduce activities: fewer checks, lighter processes, less on-site monitoring. The goal is often simple: cut time and cost. Technically and regulatorily, this interpretation is wrong.…
Digital twins in Clinical trials: a new way of designing studies
In the past year, Digital twin has become one of the most overused terms in healthcare innovation. It appears in conference slides, CRO strategy decks, and investor presentations, often described as a virtual copy of a patient, ready to be tested like an avatar in a simulation. But the reality is less cinematic and far…
MDR – Racing Against Time for Your CE Mark
The extension is here, but it’s not a safety net. Learn how to move fast, stay compliant, and protect your market share. With Regulation (EU) 2023/607, the European Commission has introduced a critical extension to MDR deadlines for legacy devices certified under the previous MDD (Directive 93/42/EEC). It’s a valuable opportunity—but not an excuse to delay.…